PURPOSE OF REVIEW: To outline the development, rationale, and practical use of therapeutic drug monitoring in patients with inflammatory bowel disease.
RECENT FINDINGS: Therapeutic drug monitoring is traditionally discussed in terms of a proactive or reactive approach. However, these terms are not always consistently defined and can be confusing when translating research to clinical practice. Personalized approaches incorporating clinical context and precision medicine are emerging. Personalized therapeutic drug monitoring combines a structured and proactive strategy for monitoring biologic concentrations as well as identification of antidrug antibody development or subtherapeutic dosing in the setting of loss of response. Optimizing biologic therapy can improve outcomes and avoid loss of response. Why, when, and how we measure drug troughs and anti-drug antibodies is a moving target, though what is known is that the appropriate and evidence-based use of this practice prevents adverse events and improves outcomes in patients with inflammatory bowel disease.
|Original language||English (US)|
|Number of pages||10|
|Journal||Current gastroenterology reports|
|State||Published - Dec 2022|
Bibliographical notePublisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
- Drug monitoring
- Inflammatory bowel diseases
- Monoclonal antibodies
- Drug Monitoring
- Inflammatory Bowel Diseases/drug therapy
PubMed: MeSH publication types
- Journal Article